Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs

See what CB Insights has to offer

Stage

Acquired | Acquired

About Mills Pharmaceuticals

Mills Pharmaceuticals owns the worldwide rights to GALE-401 (Anagrelide CR), a patented, controlled release formulation of anagrelide for the treatment of Essential Thrombocythemia (ET). GALE-401 (Anagrelide CR) contains the active ingredient anagrelide, an FDA-approved product, which has been in use since the late 1990s for the treatment of Essential Thrombocythemia (ET). GALE-401 is a reformulated, controlled release version of anagrelide that is currently only given as an immediate release (IR) version. Phase 1 studies have shown the drug to be effective at lowering platelet levels while reducing side effects that prevent patients from taking their therapy regularly.

Mills Pharmaceuticals Headquarter Location

United States

Latest Mills Pharmaceuticals News

Galena Biopharma acquires Mills Pharmaceuticals

Jan 14, 2014

US drugmaker Galena Biopharma revealed that it has acquired Mills Pharmaceuticals which has the worldwide rights to GALE401 Anagrelide CR a patented controlledrelease formulation of anagrelide.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Mills Pharmaceuticals Patents

Mills Pharmaceuticals has filed 9 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/14/2011

5/20/2014

Architectural elements, Columns and entablature, Mobile genetic elements, Molecular biology, Missile guidance

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

7/14/2011

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

5/20/2014

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Architectural elements, Columns and entablature, Mobile genetic elements, Molecular biology, Missile guidance

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.